Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

(2016) Martyn E Caplin et al.   ENDOCRINE-RELATED CANCER

Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease

(2016) Richard Rammo et al.   JOURNAL OF NEUROSURGERY

Treatment of unresectable skull base meningiomas with somatostatin analogs

(2016) Chris Schulz et al.   Neurosurgical Focus

Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas

(2015) Thomas Graillon et al.   JOURNAL OF NEURO-ONCOLOGY

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma

(2015) Julia Furtner et al.   NEURO-ONCOLOGY

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy

(2014) Marta Simó et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures

(2014) A. Mohamed et al.   ENDOCRINE-RELATED CANCER

Comparative study of soft tissue perineurioma and meningioma using a five-marker immunohistochemical panel

(2014) Abbas Agaimy et al.   HISTOPATHOLOGY

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

(2014) T. Kaley et al.   NEURO-ONCOLOGY

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

(2014) A. D. Norden et al.   NEUROLOGY

The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma

(2012) Marc C. Chamberlain   CURRENT OPINION IN ONCOLOGY

Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema

(2011) DAMOUN NASSEHI et al.   APMIS

Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes

(2011) A. Durand et al.   CLINICAL NEUROPATHOLOGY

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

(2011) D. R. Johnson et al.   NEURO-ONCOLOGY

Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function

(2011) C. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives

(2010) Marialuisa Appetecchia et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

(2010) Karine Villaume et al.   NEUROENDOCRINOLOGY

αvβ5/β6 integrin suppression leads to a stimulation of α2β1 dependent cell migration resistant to PI3K/Akt inhibition

(2009) Céline Defilles et al.   EXPERIMENTAL CELL RESEARCH

Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas

(2009) Christiaan de Bruin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling

(2009) M. A. Lopez-Lago et al.   MOLECULAR AND CELLULAR BIOLOGY

NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth

(2009) M. F. James et al.   MOLECULAR AND CELLULAR BIOLOGY

Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients

(2009) Eugene A. Woltering et al.   PANCREAS

Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas

(2008) J. Acunzo et al.   CANCER RESEARCH

Antitumor effects of somatostatin

(2008) Stéphane Pyronnet et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment

(2008) Masamichi Kurosaki et al.   NEUROLOGICAL RESEARCH